199 related articles for article (PubMed ID: 18245011)
1. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Mahtani RL; Macdonald JS
Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
[TBL] [Abstract][Full Text] [Related]
2. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in colorectal cancer.
Rajpal S; Venook AP
Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
6. [Cetuximab].
Takiuchi H
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
[TBL] [Abstract][Full Text] [Related]
7. Critical evaluation of current treatments in metastatic colorectal cancer.
Venook A
Oncologist; 2005 Apr; 10(4):250-61. PubMed ID: 15821245
[TBL] [Abstract][Full Text] [Related]
8. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
9. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Vanhoefer U
Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab plus irinotecan in refractory colorectal cancer patients.
Gil Delgado M; Spano JP; Khayat D
Expert Rev Anticancer Ther; 2007 Apr; 7(4):407-13. PubMed ID: 17428161
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
14. The role of targeted therapy in the treatment of colorectal cancer.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
17. [Which role do new therapeutic options play in palliative care of colorectal cancer?].
Verbeek W; Graeven U
Internist (Berl); 2005 Dec; 46(12):1339-46. PubMed ID: 16228155
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]